\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\:\\ pulse\\ ox\\ w\\/\\ desats\\ to\\ mid\\-80s\\ w\\/\\ exertion\\;\\ heent\\:\\ multiple\\ facial\\ angiofibromas\\,\\ gingival\\ fibromas\\,\\ multiple\\ hypomelanotic\\ macules\\,\\ no\\ lad\\;\\ cv\\:\\ rrr\\;\\ lungs\\:\\ ctab\\ but\\ diminished\\ breath\\ sounds\\ bilaterally\\;\\ skin\\:\\ confetti\\ lesions\\ x4\\ extremities\\;\\ shagreen\\â\\€\\™s\\ patch\\ on\\ back\\,\\ subungual\\ fibromas\ \(0\)\
\-\ she\\ will\\ follow\\ up\\ w\\/\\ her\\ pulmonologist\\ every\\ 6\\ months\\ w\\/\\ pfts\\ and\\ ct\\ to\\ monitor\\ progression\\ of\\ her\\ pulmonary\\ disease\\;\\ there\\ is\\ currently\\ no\\ treatment\\ for\\ her\\ disease\\ aside\\ from\\ symptomatic\\ relief\\.\\ hormone\\ replacement\\ and\\ manipulation\\ with\\ progesterone\\ and\\ luteinizing\\ hormone\\ analogs\\ with\\ or\\ without\\ oophorectomy\\ have\\ been\\ tried\\ but\\ without\\ demonstrated\\ efficacy\\.\\ lung\\ transplantation\\ may\\ also\\ be\\ considered\\ as\\ pulmonary\\ involvement\\ of\\ ts\\ usually\\ carries\\ a\\ poor\\ prognosis\\,\\ with\\ progressive\\ disease\\ and\\ death\\ secondary\\ to\\ respiratory\\ insufficiency\\ within\\ 5\\ years\\.\ \(0\)\
\-\ cxr\\:\\ left\\ and\\ probable\\ r\\ lung\\ surgery\\ w\\/\\ hyperinflation\\ and\\ scattered\\ bilateral\\ increased\\ lung\\ markings\\ c\\/w\\ lymphangioleiomyomatosis\\;\\ no\\ definite\\ evidence\\ of\\ pneumothorax\\.\\ \\ \ \(0\)\
\-\ ct\\ \\(chest\\)\\:\\ severe\\ cystic\\ changes\\ in\\ lungs\\ w\\/\\ no\\ evidence\\ of\\ ptx\\ or\\ effusion\\.\\ \ \(0\)\
\-\ prior\\ ct\\ \\(abd\\,\\ pelvis\\)\\:\\ numerous\\ bilateral\\ fatty\\ lesions\\ w\\/in\\ kidneys\\ c\\/w\\ angiomyolipoma\\;\\ multiple\\ nonfatty\\ angiomyolipomas\\ bilaterally\\;\\ enlarged\\ lymph\\ node\\ in\\ l\\ iliac\\ chain\\;\\ cystic\\ structure\\ adjacent\\ to\\ the\\ uterus\\ on\\ l\\,\\ which\\ may\\ represent\\ a\\ retroperitoneal\\ lymphangioma\\ vs\\ an\\ enlarged\\ l\\ ovary\\ w\\/\\ cyst\\;\\ inhomogenous\\ enhancement\\ of\\ the\\ uterus\\ which\\ is\\ also\\ enlarged\\ c\\/w\\ fibroids\\;\\ multiple\\ osteoblastic\\ foci\\ w\\/in\\ the\\ vertebral\\ bodies\\ \\â\\€\\“\\ study\\ unavailable\ \(0\)\
\-\ prior\\ mri\\:\\ periventricular\\ calcifications\\ \\â\\€\\“\\ study\\ unavailable\ \(0\)\
\-\ tuberous\\ sclerosis\\ w\\/\\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\\;\\ phakomatoses\\ \\(neurocutaneous\\ syndromes\\)\\ including\\ tuberous\\ sclerosis\\,\\ neurofibromatosis\\,\\ sturge\\ weber\\ disease\\,\\ von\\ hippel\\-lindau\\ syndrome\\,\\ and\\ ataxia\\ telangiectasia\\;\\ emphysema\\,\\ langerhans\\â\\€\\™\\ cell\\ histiocytosis\\ \\(eosinophilic\\ granuloma\\)\\;\\ lymphangioleiomyomatosis\\;\\ interstitial\\ pulmonary\\ fibrosis\\;\\ sarcoidosis\\;\\ pulmonary\\ lymphangiectasis\\;\\ diffuse\\ pulmonary\\ lymphangiomatosis\\,\\ lymphangiomas\\;\\ uterine\\ leiomyosarcoma\\ w\\/\\ lung\\ mets\\;\\ benign\\ metastasizing\\ uterine\\ leiomyomata\\;\\ mesenchymal\\ cystic\\ hamartoma\\ of\\ the\\ lung\\;\\ multiple\\ pulmonary\\ fibroleiomyomatosis\\ hamartomas\\ \\(very\\ rare\\)\ \(0\)\
\-\ 36\\ y\\/o\\ female\\ w\\/\\ a\\ history\\ of\\ complex\\ partial\\ seizures\\ since\\ childhood\\ and\\ two\\ episodes\\ of\\ spontaneous\\ pneumothorax\\ in\\ the\\ last\\ year\\ treated\\ w\\/\\ drainage\\ pleurodesis\\/\\ pleurectomy\\ reports\\ continued\\ dyspnea\\ on\\ exertion\\.\\ she\\ currently\\ takes\\ no\\ medications\\ and\\ has\\ no\\ family\\ history\\ of\\ any\\ problems\\.\ \(0\)\
\-\ tuberous\\ sclerosis\\ is\\ a\\ genetic\\ neurocutaneous\\ disorder\\ that\\ is\\ autosomal\\ dominant\\ in\\ the\\ one\\-third\\ of\\ familial\\ cases\\ or\\ either\\ due\\ to\\ spontaneous\\ mutation\\ or\\ mosaicism\\ in\\ non\\-familial\\ cases\\.\\ the\\ defect\\ is\\ in\\ the\\ tsc1\\ \\(chromosome\\ 9\\)\\ and\\ tsc2\\ \\(chromosome\\ 16p\\)\\ genes\\,\\ which\\ code\\ for\\ the\\ proteins\\ hamartin\\ and\\ tuberin\\ respectively\\,\\ although\\ the\\ functions\\ of\\ these\\ proteins\\ are\\ as\\ yet\\ unknown\\.\\ ts\\ manifests\\ with\\ multi\\-organ\\ involvement\\,\\ with\\ dermatologic\\ features\\ including\\ hypopigmented\\ lesions\\ \\(ash\\-leaf\\ spots\\)\\ and\\ connective\\ tissue\\ nevi\\ \\(shagreen\\ patch\\)\\,\\ and\\ cns\\ involvement\\ including\\ periventricular\\ calcifications\\ and\\ seizure\\ disorders\\,\\ often\\ with\\ severe\\ learning\\ difficulties\\,\\ mental\\ retardation\\,\\ and\\ autism\\.\\ pulmonary\\ manifestions\\ often\\ show\\ an\\ obstructive\\ pattern\\ on\\ pfts\\ with\\ interstitial\\ disease\\ with\\ cystic\\ changes\\ on\\ radiographs\\ and\\ ct\\ that\\ are\\ indistinguishable\\ from\\ lymphangioleiomyomatosis\\ \\(lam\\)\\.\\ it\\ predominantly\\ affects\\ females\\ in\\ the\\ fourth\\ decade\\,\\ often\\ presenting\\ with\\ dyspnea\\ from\\ spontaneous\\ pneumorthorax\\ in\\ up\\ to\\ a\\ third\\,\\ chronic\\ cough\\,\\ and\\/or\\ wheezing\\ with\\ chest\\ pain\\ and\\ can\\ lead\\ to\\ cyanosis\\,\\ cor\\ pulmonale\\,\\ and\\ death\\ from\\ respiratory\\ failure\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ w\\/\\:\\ 0\\.0819637137516282\ \(0\)\
\-\ \\;\\:\\ 0\\.0782935921586717\ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.051903034406312935\ \(0\)\
\-\ pulmonary\\:\\ 0\\.03776294586887491\ \(0\)\
\-\ lam\\:\\ 0\\.031919050962244525\ \(0\)\
\-\ c\\/w\\:\\ 0\\.029874689072623535\ \(0\)\
\-\ shagreen\\:\\ 0\\.025939180286717274\ \(0\)\
\-\ w\\/in\\:\\ 0\\.024972181723854143\ \(0\)\
\-\ tuberous\\:\\ 0\\.023720896940133716\ \(0\)\
\-\ neurocutaneous\\:\\ 0\\.023609273797440145\ \(0\)\
\-\ proteins\\:\\ 0\\.023091120251802304\ \(0\)\
\-\ fibromas\\:\\ 0\\.022642275234577017\ \(0\)\
\-\ pfts\\:\\ 0\\.022642275234577017\ \(0\)\
\-\ ts\\:\\ 0\\.02189221287721833\ \(0\)\
\-\ chromosome\\:\\ 0\\.02127936730816302\ \(0\)\
\-\ lung\\:\\ 0\\.020799656472594505\ \(0\)\
\-\ spontaneous\\:\\ 0\\.020103553042004358\ \(0\)\
\-\ patch\\:\\ 0\\.01973472082285734\ \(0\)\
\-\ l\\:\\ 0\\.019641365536832135\ \(0\)\
\-\ unavailable\\:\\ 0\\.017982462256022763\ \(0\)\
\-\ \\:\\:\\ 0\\.017096593855320984\ \(0\)\
\-\ exertion\\:\\ 0\\.016836490535113206\ \(0\)\
\-\ cystic\\:\\ 0\\.01656895937648241\ \(0\)\
\-\ periventricular\\:\\ 0\\.016550245801196208\ \(0\)\
\-\ hormone\\:\\ 0\\.01628647566525841\ \(0\)\
\-\ involvement\\:\\ 0\\.01579128734434193\ \(0\)\
\-\ including\\:\\ 0\\.015556732643661801\ \(0\)\
\-\ death\\:\\ 0\\.015498574133027002\ \(0\)\
\-\ sclerosis\\:\\ 0\\.015475538992065606\ \(0\)\
\-\ multiple\\:\\ 0\\.01512442019730478\ \(0\)\
\-\ desats\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ mid\\-80s\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ confetti\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ lymphangiectasis\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ fibroleiomyomatosis\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ pleurodesis\\/\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ mosaicism\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ tsc1\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ 16p\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ hamartin\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ multi\\-organ\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ pneumorthorax\\:\\ 0\\.0148159973512042\ \(0\)\
\-\ uterine\\:\\ 0\\.014738492857556922\ \(0\)\
\-\ enlarged\\:\\ 0\\.014700610438910957\ \(0\)\
\-\ \\(\\:\\ 0\\.014568639857019037\ \(0\)\
\-\ \\)\\:\\ 0\\.014390676143461616\ \(0\)\
\-\ interstitial\\:\\ 0\\.014053073733569286\ \(0\)\
\-\ often\\:\\ 0\\.013746925454720936\ \(0\)\
\-\ angiofibromas\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ hypomelanotic\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ subungual\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ luteinizing\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ lymphangiomatosis\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ non\\-familial\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ tsc2\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ tuberin\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ ash\\-leaf\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ nevi\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ manifestions\\:\\ 0\\.013651044106565636\ \(0\)\
\-\ dyspnea\\:\\ 0\\.013596079998322129\ \(0\)\
\-\ uterus\\:\\ 0\\.01353958548297295\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.01348402480414535\ \(0\)\
\-\ gingival\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ ptx\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ nonfatty\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ lymphangiomas\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ leiomyomata\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ dermatologic\\:\\ 0\\.012969590143358637\ \(0\)\
\-\ her\\:\\ 0\\.012955016765470265\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.012926739913917639\ \(0\)\
\-\ analogs\\:\\ 0\\.012486090861927071\ \(0\)\
\-\ metastasizing\\:\\ 0\\.012486090861927071\ \(0\)\
\-\ pleurectomy\\:\\ 0\\.012486090861927071\ \(0\)\
\-\ autism\\:\\ 0\\.012486090861927071\ \(0\)\
\-\ pulmonale\\:\\ 0\\.012486090861927071\ \(0\)\
\-\ ox\\:\\ 0\\.012111059683247728\ \(0\)\
\-\ inhomogenous\\:\\ 0\\.012111059683247728\ \(0\)\
\-\ phakomatoses\\:\\ 0\\.012111059683247728\ \(0\)\
\-\ code\\:\\ 0\\.012111059683247728\ \(0\)\
\-\ respiratory\\:\\ 0\\.011924908453456035\ \(0\)\
\-\ disease\\:\\ 0\\.011737290262316841\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.011545560125901152\ \(0\)\
\-\ genes\\:\\ 0\\.011545560125901152\ \(0\)\
\-\ hypopigmented\\:\\ 0\\.011545560125901152\ \(0\)\
\-\ learning\\:\\ 0\\.011545560125901152\ \(0\)\
\-\ lesions\\:\\ 0\\.011533918519381249\ \(0\)\
\-\ currently\\:\\ 0\\.011382093428611958\ \(0\)\
\-\ \\,\\:\\ 0\\.011374372500726362\ \(0\)\
\-\ progesterone\\:\\ 0\\.011321137617288509\ \(0\)\
\-\ functions\\:\\ 0\\.011321137617288509\ \(0\)\
\-\ macules\\:\\ 0\\.011123182935513074\ \(0\)\
\-\ x4\\:\\ 0\\.011123182935513074\ \(0\)\
\-\ sturge\\:\\ 0\\.011123182935513074\ \(0\)\
\-\ lungs\\:\\ 0\\.010876600329345466\ \(0\)\
\-\ pulmonologist\\:\\ 0\\.010785921262467442\ \(0\)\
\-\ cor\\:\\ 0\\.010785921262467442\ \(0\)\
\-\ calcifications\\:\\ 0\\.010679542032379\ \(0\)\
\-\ indistinguishable\\:\\ 0\\.010505158094966322\ \(0\)\
\-\ manifests\\:\\ 0\\.010380606881262588\ \(0\)\
\-\ carries\\:\\ 0\\.010264652475402165\ \(0\)\
\-\ angiomyolipomas\\:\\ 0\\.010264652475402165\ \(0\)\
\-\ hamartomas\\:\\ 0\\.010264652475402165\ \(0\)\
\-\ one\\-third\\:\\ 0\\.010264652475402165\ \(0\)\
\-\ weber\\:\\ 0\\.010156184372649944\ \(0\)\
\-\ aside\\:\\ 0\\.010054294251950055\ \(0\)\
\-\ tried\\:\\ 0\\.010054294251950055\ \(0\)\
\-\ efficacy\\:\\ 0\\.010054294251950055\ \(0\)\
\-\ spots\\:\\ 0\\.010054294251950055\ \(0\)\
\-\ lad\\:\\ 0\\.0097811531939706\ \(0\)\
\-\ hyperinflation\\:\\ 0\\.0097811531939706\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.0097811531939706\ \(0\)\
\-\ chain\\:\\ 0\\.009699152918055589\ \(0\)\
\-\ telangiectasia\\:\\ 0\\.009699152918055589\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.009699152918055589\ \(0\)\
\-\ retardation\\:\\ 0\\.009699152918055589\ \(0\)\
\-\ cases\\:\\ 0\\.00956911214783574\ \(0\)\
\-\ transplantation\\:\\ 0\\.009546259173172015\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.009474730409442945\ \(0\)\
\-\ study\\:\\ 0\\.009450861703730955\ \(0\)\
\-\ bilaterally\\:\\ 0\\.009434303322769424\ \(0\)\
\-\ lymphangioma\\:\\ 0\\.009276775727667512\ \(0\)\
\-\ difficulties\\:\\ 0\\.009276775727667512\ \(0\)\
\-\ fibroids\\:\\ 0\\.009215653636624025\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.009215653636624025\ \(0\)\
\-\ mutation\\:\\ 0\\.009156676628537856\ \(0\)\
\-\ von\\:\\ 0\\.00904459028484261\ \(0\)\
\-\ ctab\\:\\ 0\\.00888934100731149\ \(0\)\
\-\ severe\\:\\ 0\\.008838016134675645\ \(0\)\
\-\ takes\\:\\ 0\\.008793276446235947\ \(0\)\
\-\ familial\\:\\ 0\\.008793276446235947\ \(0\)\
\-\ no\\:\\ 0\\.0086767477381896\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.00865875088712076\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.008584963830741029\ \(0\)\
\-\ manipulation\\:\\ 0\\.008534199673417025\ \(0\)\
\-\ from\\:\\ 0\\.008513853533809831\ \(0\)\
\-\ langerhans\\:\\ 0\\.00849465261894611\ \(0\)\
\-\ connective\\:\\ 0\\.008456014773190315\ \(0\)\
\-\ decade\\:\\ 0\\.008456014773190315\ \(0\)\
\-\ cyanosis\\:\\ 0\\.008418245267556603\ \(0\)\
\-\ autosomal\\:\\ 0\\.008309777164804383\ \(0\)\
\-\ wheezing\\:\\ 0\\.008309777164804383\ \(0\)\
\-\ probable\\:\\ 0\\.008275122900598104\ \(0\)\
\-\ mets\\:\\ 0\\.008275122900598104\ \(0\)\
\-\ respectively\\:\\ 0\\.008275122900598104\ \(0\)\
\-\ changes\\:\\ 0\\.00823209403776491\ \(0\)\
\-\ syndromes\\:\\ 0\\.008207887044104491\ \(0\)\
\-\ monitor\\:\\ 0\\.008175251605689195\ \(0\)\
\-\ affects\\:\\ 0\\.008175251605689195\ \(0\)\
\-\ childhood\\:\\ 0\\.00808098359451097\ \(0\)\
\-\ she\\:\\ 0\\.008063146693963604\ \(0\)\
\-\ yet\\:\\ 0\\.00805070039198546\ \(0\)\
\-\ which\\:\\ 0\\.008042745818029658\ \(0\)\
\-\ ct\\:\\ 0\\.008035654812719617\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.007991723383899293\ \(0\)\
\-\ females\\:\\ 0\\.007991723383899293\ \(0\)\
\-\ cv\\:\\ 0\\.007962993243799628\ \(0\)\
\-\ markings\\:\\ 0\\.007962993243799628\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.00793474598612504\ \(0\)\
\-\ diminished\\:\\ 0\\.007852745710210027\ \(0\)\
\-\ emphysema\\:\\ 0\\.007852745710210027\ \(0\)\
\-\ hamartoma\\:\\ 0\\.007852745710210027\ \(0\)\
\-\ genetic\\:\\ 0\\.007852745710210027\ \(0\)\
\-\ definite\\:\\ 0\\.0077745608099833155\ \(0\)\
\-\ ovary\\:\\ 0\\.007749287066513501\ \(0\)\
\-\ up\\:\\ 0\\.007723855969930163\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.007699851965326452\ \(0\)\
\-\ ataxia\\:\\ 0\\.007675669213306116\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.00765182949063056\ \(0\)\
\-\ every\\:\\ 0\\.007628323201597384\ \(0\)\
\-\ insufficiency\\:\\ 0\\.007628323201597384\ \(0\)\
\-\ abd\\:\\ 0\\.0076051411475934584\ \(0\)\
\-\ evidence\\:\\ 0\\.007530899439888665\ \(0\)\
\-\ fatty\\:\\ 0\\.007451246704693473\ \(0\)\
\-\ pulse\\:\\ 0\\.007409746515465958\ \(0\)\
\-\ obstructive\\:\\ 0\\.007389374480957816\ \(0\)\
\-\ prior\\:\\ 0\\.007375168982192819\ \(0\)\
\-\ cns\\:\\ 0\\.007349356583993583\ \(0\)\
\-\ rrr\\:\\ 0\\.007329699374307547\ \(0\)\
\-\ relief\\:\\ 0\\.007329699374307547\ \(0\)\
\-\ dominant\\:\\ 0\\.007329699374307547\ \(0\)\
\-\ 36\\:\\ 0\\.007198183076997046\ \(0\)\
\-\ iliac\\:\\ 0\\.007162422743472198\ \(0\)\
\-\ progression\\:\\ 0\\.007144823920165819\ \(0\)\
\-\ episodes\\:\\ 0\\.0070931068467763175\ \(0\)\
\-\ granuloma\\:\\ 0\\.007059492280882754\ \(0\)\
\-\ replacement\\:\\ 0\\.007010298361050632\ \(0\)\
\-\ bilateral\\:\\ 0\\.006970815896855274\ \(0\)\
\-\ heent\\:\\ 0\\.006946869238390384\ \(0\)\
\-\ fourth\\:\\ 0\\.006946869238390384\ \(0\)\
\-\ lead\\:\\ 0\\.006885747147346897\ \(0\)\
\-\ chest\\:\\ 0\\.006873038655655525\ \(0\)\
\-\ vitals\\:\\ 0\\.006870807739922954\ \(0\)\
\-\ disorders\\:\\ 0\\.006870807739922954\ \(0\)\
\-\ prognosis\\:\\ 0\\.006812343679275197\ \(0\)\
\-\ without\\:\\ 0\\.006763069466750119\ \(0\)\
\-\ or\\:\\ 0\\.006732926043453496\ \(0\)\
\-\ bodies\\:\\ 0\\.006728292552258959\ \(0\)\
\-\ predominantly\\:\\ 0\\.006728292552258959\ \(0\)\
\-\ mental\\:\\ 0\\.006701184347334786\ \(0\)\
\-\ scattered\\:\\ 0\\.006687792465571463\ \(0\)\
\-\ problems\\:\\ 0\\.006648245411100548\ \(0\)\
\-\ kidneys\\:\\ 0\\.006609607565344752\ \(0\)\
\-\ node\\:\\ 0\\.00657183805971104\ \(0\)\
\-\ r\\:\\ 0\\.006522763850144213\ \(0\)\
\-\ structure\\:\\ 0\\.006522763850144213\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.006486876245991996\ \(0\)\
\-\ poor\\:\\ 0\\.0064633699569588195\ \(0\)\
\-\ disorder\\:\\ 0\\.006451738960581385\ \(0\)\
\-\ numerous\\:\\ 0\\.006440187902954895\ \(0\)\
\-\ medications\\:\\ 0\\.006406003559699226\ \(0\)\
\-\ fibrosis\\:\\ 0\\.0063947615628071304\ \(0\)\
\-\ seizure\\:\\ 0\\.006350530792525831\ \(0\)\
\-\ represent\\:\\ 0\\.006307434270486608\ \(0\)\
\-\ may\\:\\ 0\\.006300263424867643\ \(0\)\
\-\ either\\:\\ 0\\.0062550726439659435\ \(0\)\
\-\ facial\\:\\ 0\\.006244793270827395\ \(0\)\
\-\ continued\\:\\ 0\\.0061844033393550196\ \(0\)\
\-\ seizures\\:\\ 0\\.006174545995737544\ \(0\)\
\-\ foci\\:\\ 0\\.0061647461296689835\ \(0\)\
\-\ last\\:\\ 0\\.006135684789988209\ \(0\)\
\-\ but\\:\\ 0\\.006126061516079118\ \(0\)\
\-\ on\\:\\ 0\\.006083117750969984\ \(0\)\
\-\ and\\/or\\:\\ 0\\.006069767625024711\ \(0\)\
\-\ cxr\\:\\ 0\\.006060558438865677\ \(0\)\
\-\ features\\:\\ 0\\.006060558438865677\ \(0\)\
\-\ drainage\\:\\ 0\\.006006338502364464\ \(0\)\
\-\ 9\\:\\ 0\\.005936663353325227\ \(0\)\
\-\ family\\:\\ 0\\.005886239403234808\ \(0\)\
\-\ presenting\\:\\ 0\\.00585344475748089\ \(0\)\
\-\ considered\\:\\ 0\\.0057975502671338604\ \(0\)\
\-\ lymph\\:\\ 0\\.0057975502671338604\ \(0\)\
\-\ reports\\:\\ 0\\.00578971495098964\ \(0\)\
\-\ third\\:\\ 0\\.005758733939747895\ \(0\)\
\-\ complex\\:\\ 0\\.005751077105233844\ \(0\)\
\-\ partial\\:\\ 0\\.005743454995712178\ \(0\)\
\-\ sounds\\:\\ 0\\.005728313701691395\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0057058544952843905\ \(0\)\
\-\ vertebral\\:\\ 0\\.005683691462877745\ \(0\)\
\-\ progressive\\:\\ 0\\.0056763682605769795\ \(0\)\
\-\ in\\:\\ 0\\.005665845111129478\ \(0\)\
\-\ also\\:\\ 0\\.0056625868694795\ \(0\)\
\-\ vs\\:\\ 0\\.005654588185547559\ \(0\)\
\-\ extremities\\:\\ 0\\.005633086754522502\ \(0\)\
\-\ failure\\:\\ 0\\.005625980307279608\ \(0\)\
\-\ unknown\\:\\ 0\\.00560483949684791\ \(0\)\
\-\ rare\\:\\ 0\\.005577059157434111\ \(0\)\
\-\ skin\\:\\ 0\\.005516183084435257\ \(0\)\
\-\ cough\\:\\ 0\\.005502949376148021\ \(0\)\
\-\ pattern\\:\\ 0\\.005489819057262653\ \(0\)\
\-\ effusion\\:\\ 0\\.005457435160009078\ \(0\)\
\-\ and\\:\\ 0\\.005445650593579718\ \(0\)\
\-\ defect\\:\\ 0\\.005376045926554499\ \(0\)\
\-\ breath\\:\\ 0\\.005369945476049325\ \(0\)\
\-\ since\\:\\ 0\\.0052752346583163304\ \(0\)\
\-\ pelvis\\:\\ 0\\.005218641019481729\ \(0\)\
\-\ very\\:\\ 0\\.005213085073037192\ \(0\)\
\-\ to\\:\\ 0\\.005024330687564544\ \(0\)\
\-\ that\\:\\ 0\\.004961279759861591\ \(0\)\
\-\ benign\\:\\ 0\\.004956387171484372\ \(0\)\
\-\ although\\:\\ 0\\.004850301311893452\ \(0\)\
\-\ back\\:\\ 0\\.004737926614029373\ \(0\)\
\-\ is\\:\\ 0\\.004725132591468282\ \(0\)\
\-\ follow\\:\\ 0\\.00456336045705283\ \(0\)\
\-\ radiographs\\:\\ 0\\.004548354354961568\ \(0\)\
\-\ adjacent\\:\\ 0\\.004540901250645828\ \(0\)\
\-\ any\\:\\ 0\\.004522411820289569\ \(0\)\
\-\ will\\:\\ 0\\.004493245409040575\ \(0\)\
\-\ show\\:\\ 0\\.00440866543612038\ \(0\)\
\-\ usually\\:\\ 0\\.004361223956078587\ \(0\)\
\-\ diffuse\\:\\ 0\\.004347911630882883\ \(0\)\
\-\ as\\:\\ 0\\.004344798339139926\ \(0\)\
\-\ treated\\:\\ 0\\.004298908968208167\ \(0\)\
\-\ 6\\:\\ 0\\.004289277582142646\ \(0\)\
\-\ years\\:\\ 0\\.004217215356333584\ \(0\)\
\-\ demonstrated\\:\\ 0\\.004214151231020114\ \(0\)\
\-\ 5\\:\\ 0\\.004201950289822123\ \(0\)\
\-\ s\\:\\ 0\\.004118937255654769\ \(0\)\
\-\ two\\:\\ 0\\.0041131617438924465\ \(0\)\
\-\ syndrome\\:\\ 0\\.0041074060113187255\ \(0\)\
\-\ chronic\\:\\ 0\\.00404536072757479\ \(0\)\
\-\ secondary\\:\\ 0\\.004015176414300517\ \(0\)\
\-\ y\\/o\\:\\ 0\\.003977527781209481\ \(0\)\
\-\ an\\:\\ 0\\.003971982737091529\ \(0\)\
\-\ history\\:\\ 0\\.0039671076897717095\ \(0\)\
\-\ months\\:\\ 0\\.003922590411243811\ \(0\)\
\-\ are\\:\\ 0\\.0039155424286709305\ \(0\)\
\-\ been\\:\\ 0\\.003907218301620154\ \(0\)\
\-\ cell\\:\\ 0\\.0038793961539184646\ \(0\)\
\-\ cyst\\:\\ 0\\.003859447287438828\ \(0\)\
\-\ enhancement\\:\\ 0\\.0038495609514672875\ \(0\)\
\-\ due\\:\\ 0\\.0038323985763913273\ \(0\)\
\-\ these\\:\\ 0\\.003737554104130824\ \(0\)\
\-\ increased\\:\\ 0\\.0035134198013439593\ \(0\)\
\-\ surgery\\:\\ 0\\.003487393385479454\ \(0\)\
\-\ tissue\\:\\ 0\\.0034040692242900735\ \(0\)\
\-\ a\\:\\ 0\\.0033327714438537923\ \(0\)\
\-\ mri\\:\\ 0\\.00329962328557079\ \(0\)\
\-\ can\\:\\ 0\\.0032575165587715458\ \(0\)\
\-\ it\\:\\ 0\\.0032283166126605323\ \(0\)\
\-\ have\\:\\ 0\\.00310997996363881\ \(0\)\
\-\ female\\:\\ 0\\.002952538271340897\ \(0\)\
\-\ treatment\\:\\ 0\\.002906919259833424\ \(0\)\
\-\ within\\:\\ 0\\.0027397166527497172\ \(0\)\
\-\ has\\:\\ 0\\.0026969747403265175\ \(0\)\
\-\ the\\:\\ 0\\.0025558691289745946\ \(0\)\
\-\ for\\:\\ 0\\.0024507836929166895\ \(0\)\
\-\ be\\:\\ 0\\.0022147171820906374\ \(0\)\
\-\ of\\:\\ 0\\.0021538517794586097\ \(0\)\
\-\ there\\:\\ 0\\.0021373370696890566\ \(0\)\
\-\ with\\:\\ 0\\.00196645674100655\ \(0\)\
\-\ pain\\:\\ 0\\.001753963306774344\ \(0\)\
\-\ left\\:\\ 0\\.001606899612223386\ \(0\)\
\-\ year\\:\\ 0\\.001606899612223386\ \(0\)\
\-\ \\.\\:\\ 0\\.0007159570305347149\ \(0\)\
